More screening criteria, expanded procedures, new vendor systems and tools, and increased data collection. So who bears the burden of all this progress? Sites.
Increased site burden means degraded performance, additional delays, and more problems for you. But it doesn't have to be that way.
Watch this webinar, as we discuss real clinical trial examples from emerging biotechs that will give you techniques to identify and mitigate risks sooner in your study, by: